These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23698253)

  • 21. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).
    Kollmannsberger C; Hirte H; Siu LL; Mazurka J; Chi K; Elit L; Walsh W; Sederias J; Doyle A; Eisenhauer EA; Oza AM
    Ann Oncol; 2012 Jan; 23(1):238-244. PubMed ID: 21447615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
    Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
    Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
    Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
    Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
    J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
    Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Janku F; Zinner R; Laday S; Kies M; Tsimberidou AM
    Invest New Drugs; 2013 Dec; 31(6):1505-13. PubMed ID: 23982248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
    Abu-Khalaf MM; Baumgart MA; Gettinger SN; Doddamane I; Tuck DP; Hou S; Chen N; Sullivan C; Lezon-Geyda K; Zelterman D; Hatzis C; Deshpande H; Digiovanna MP; Azodi M; Schwartz PE; Harris LN
    Cancer; 2015 Jun; 121(11):1817-26. PubMed ID: 25649370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of temsirolimus and metformin in advanced solid tumours.
    MacKenzie MJ; Ernst S; Johnson C; Winquist E
    Invest New Drugs; 2012 Apr; 30(2):647-52. PubMed ID: 20978924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
    Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
    J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.
    Morgenstern DA; Marzouki M; Bartels U; Irwin MS; Sholler GL; Gammon J; Yankanah R; Wu B; Samson Y; Baruchel S
    Pediatr Blood Cancer; 2014 Jan; 61(1):128-33. PubMed ID: 23956145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
    Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
    Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
    Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
    Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
    Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
    Park H; Garrido-Laguna I; Naing A; Fu S; Falchook GS; Piha-Paul SA; Wheler JJ; Hong DS; Tsimberidou AM; Subbiah V; Zinner RG; Kaseb AO; Patel S; Fanale MA; Velez-Bravo VM; Meric-Bernstam F; Kurzrock R; Janku F
    Oncotarget; 2016 Oct; 7(41):67521-67531. PubMed ID: 27589687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
    McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
    Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
    Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
    Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
    Burris HA; Dowlati A; Moss RA; Infante JR; Jones SF; Spigel DR; Levinson KT; Lindquist D; Gainer SD; Dar MM; Suttle AB; Ball HA; Tan AR
    Mol Cancer Ther; 2012 Aug; 11(8):1820-8. PubMed ID: 22679111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.